Big Pharma's $43B playbook is repeating - here's who's running it

The small biotech following Seagen's $43B path to precision ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­  

You are receiving this email because you are subscribed to Morning Watchlist from Behind the Markets. If you no longer wish to receive these partner emails, please unsubscribe here. This message is from Edge on the Street. This patented biotech platform could power 100's of cancer drugs. See who:...                               The $43B Blueprint Is Back. When Pfizer bought Seagen for $43 billion, it wasn't just buying a company - it was buying precision. Seagen's antibody-drug conjugates (ADCs) proved that if you can guide chemotherapy directly to the tumor, you can make chemo powerful again. Now, a new player looks to take that idea further. Its breakthrough technology acts as a laser-guided system inside the cell, ensuring that once the drug finds the tumor, the toxic payload is delivered exactly where it's needed - not throughout the body. Early data suggest higher potency at lower doses - a combination that could make ADCs not only stronger, but safer. And here's the real kicker: this isn't a single-drug story. The same platform can potentially plug into hundreds of existing therapies - from ADCs to vaccines to radiotherapies - upgrading how modern medicine delivers its payloads. Seagen proved precision pays. This next generation aims to make it universal. Discover the breakthrough reshaping oncology We are issuing this disclosure in compliance with Section 17(b) of the Securities Act, which requires us to disclose any compensation received or expected to be received in cash or in kind in connection with the purchase or sale of any security. We would like to inform you that we have received or expect to receive compensation in connection with the purchase or sale of the securities of Defence Therapeutics (OTC: DTCFF). The compensation consists of  up to $6,000 and was received/will be received from i2i Marketing Group. This communication should not be considered as an endorsement of the securities of adviser Defence Therapeutics (OTC: DTCFF) and we are not responsible for any errors or omissions in any information provided about the securities of Defence Therapeutics (OTC: DTCFF) by Edge on the Street or i2i Merketing Group. We encourage you to conduct your own due diligence and research before making any investment decisions. You should also consult with a financial advisor before making any investment decisions. This disclosure is made as of 11/20/2025. Our mailing address is: Behind the Markets, LLC 4260 NW 1st Avenue, Suite 55 Boca Raton, FL 33431 Copyright © 2024 Behind the Markets, LLC, All rights reserved. You're receiving this email as part of your subscription to Behind the Markets. For more information about our privacy practices, please review our Privacy Policy or our Legal Notices. Behind the Markets You are receiving this email because you are subscribed to Morning Watchlist from Behind the Markets. If you no longer wish to receive these partner emails, please unsubscribe here. Today's Bonus Content: 5 Stocks That Could Double Your Investment in 2025 (By clicking this link you agree to receive emails from Trading Tips and our affiliates. You can opt out at any time. - Privacy Policy)